CELL INTELLIGENCE · 肿瘤细胞治疗研究

CELLIN 肿瘤细胞治疗研究

← 返回

慢性淋巴细胞白血病和 CLL 样单克隆 B 细胞淋巴细胞增多症中 CD94/NKG2C(+) NK 细胞扩增减少与人类巨细胞病毒血清阴性增加或 NKG2C 缺失无关

英文原题：Reduced expansion of CD94/NKG2C(+) NK cells in chronic lymphocytic leukemia and CLL-like monoclonal B-cell lymphocytosis is not related to increased human cytomegalovirus seronegativity or NKG2C deletions.

查看英文原题

Reduced expansion of CD94/NKG2C(+) NK cells in chronic lymphocytic leukemia and CLL-like monoclonal B-cell lymphocytosis is not related to increased human cytomegalovirus seronegativity or NKG2C deletions.

PubMed 2021/02/22（内容时间） Int J Lab Hematol Q3 · IF 2.2（JCR 2025）

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

技术：NK 细胞慢性淋巴细胞白血病地区：欧洲
登录后收藏与关注 全文解读登录并开通会员后使用加入对比登录并开通会员后使用

研究概要

在 CLL 和 MBL 患者中观察到 CD94/NKG2C+ NK 细胞百分比降低，这一现象与 HCMV 血清状态和 NKG2C 基因型无关，尤其是在淋巴细胞增多加剧的 CLL 患者中，这可能与肿瘤细胞的暴露有关。

中文摘要

方法

研究者分析了 24 例 MBL 和 37 例 CLL 患者中 NKG2A、NKG2C、ILT2、KIR、CD161 和 CD57 的表达；对这些患者及另外 81 例 MBL/CLL 患者进行 NKG2C 基因分型，并检测 26 例患者的 NKG2C 基因表达。对 8 例淋巴细胞增多（≥20×10⁹/L）的 CLL 患者评估肿瘤 HLA-E 和 HLA-G 表达。

结果

MBL 与 CLL 患者的 NKR 分布无显著差异，但与非 CLL 组相比，两者 NKG2C⁺ NK 细胞比例较低（4.6% 对 12.2%，P=0.012）。HCMV 阳性者的 NKG2C⁺ NK 细胞比例高于阴性者（7.3% 对 2.9%，P=0.176）。MBL/CLL 中 NKG2C 缺失频率与一般人群相似。NKG2C 表达低或检测不到者在 NKG2C⁺/− 和 NKG2C⁺/⁺ 患者中分别占 45% 和 12%。淋巴细胞增多的 CLL 病例 NKG2C 表达尤其低（1.8% 对 8.1%，P=0.029）；其肿瘤细胞 HLA-E 高表达（>98%），HLA-G 表达不一（12.4%，范围 0.5%–56.4%）。NKG2C 表达低于 7% 的 CLL 患者至首次治疗时间更短（P=0.037）。

结论

无论 HCMV 血清状态和 NKG2C 合子型如何，CLL 和 MBL 患者的 CD94/NKG2C⁺ NK 细胞比例均降低，淋巴细胞增多的 CLL 患者尤为明显；这可能与接触肿瘤细胞有关。

展开英文摘要原文
METHODS

We analyzed the expression of NKG2A, NKG2C, ILT2, KIR, CD161, and CD57 in 24 MBL and 37 CLL. NKG2C was genotyped in these patients and in 81 additional MBL/CLL, while NKG2C gene expression was assessed in 26 cases. In 8 CLL patients with increased lymphocytosis ( 20 10 9 /L), tumor HLA-E and HLA-G expression was evaluated.

RESULTS

NKR distribution did not significantly differ between MBL and CLL patients, although they exhibited reduced NKG2C + NK cells compared with a non-CLL group (4.6% vs 12.2%, P = .012). HCMV + patients showed increased percentages of NKG2C + NK cells compared with HCMV - (7.3% vs 2.9%, P = .176). Frequencies of NKG2C deletions in MBL/CLL were similar to those of the general population. Low/undetectable NKG2C expression was found among NKG2C +/- (45%) and NKG2C +/+ (12%) patients. CLL cases with increased lymphocytosis displayed especially reduced NKG2C expression (1.8% vs 8.1%, P = .029) and tumor cells with high HLA-E (>98%) and variable HLA-G expression (12.4%, range: 0.5-56.4). CLL patients with low NKG2C expression (<7%) showed shorter time to first treatment (P = .037).

CONCLUSION

Reduced percentages of CD94/NKG2C + NK cells were observed in CLL and MBL patients independently of HCMV serostatus and NKG2C zygosity, particularly in CLL patients with increased lymphocytosis, which could potentially be related to the exposure to tumor cells.

论文信息

作者
Puiggros A、Blanco G、Muntasell A、Rodríguez-Rivera M、Nonell L、Altadill M、Puigdecanet E、Arnal M
单位
Molecular Cytogenetics Laboratory, Hematological Cytology Laboratory, Pathology Department, Hospital del Mar, Barcelona, Spain.Spain
期刊
International journal of laboratory hematology2021 Oct
原文标识
PubMed 33615729　·　DOI 10.1111/ijlh.13494

在 PubMed 查看 → 出版商原文（DOI） 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →